Biosequence has chosen OncoDNA as its preferred supplier of clinical grade molecular diagnostics for cancer using the OncoDEEP cancer panel

Biosequence has chosen OncoDNA as its preferred supplier of clinical grade molecular diagnostics for cancer using the OncoDEEP cancer panel

Brussels & Valencia, 3rd March 2015

Belgium based OncoDNA SA, The Cancer Theranostic Company, which performs DNA next
generation sequencing (NGS) and molecular pathology (IHCs) to provide oncologists with drug
treatment recommendations, has recently finalized a distribution agreement with BioSequence,
the leading personalized cancer genomics provider in Spain to bring affordable and state-of-theart
theranostic analyses to the Spanish population.

BioSequence has chosen OncoDNA as its preferred supplier of clinical grade molecular
theranostic using the OncoDEEP DX and Clinical cancer panels in combination with the
Package PLUS, a cancer specific package of different IHCs and other tests designed to analyse
key proteins’ presence and activity, translocations, etc. The collaboration agreement with
OncoDNA will enable Spanish physicians to access medical innovations based on next gen
sequencing, providing them with clinically relevant interpretations of patients' tumors by using
the OncoSHARE web platform designed by OncoDNA.

This collaboration agreement confers distribution exclusivity in Spain for BIOSEQUENCE. This
is the ninth (9) exclusive agreement granted by OncoDNA.
OncoDNA’s aim is to provide medical innovations based on targeted sequencing or on the
complete sequencing of tumor genomes, complemented with molecular pathology testing, in
order to assist medical doctors in their treatment choices and/or provide better monitoring of the
evolution of their patients’ tumor. OncoDNA is an affiliated company of IPG (Institute of
Pathology and Genetics) in Belgium.

BioSequence provides genetic studies to customize and enhance treatment options for patients
with cancer. BioSequence selects the most appropriate genomic studies for each type of tumor,
always seeking the maximum clinical utility for the patient. BioSequence uses the latest
technologies for analysis and interpretation and supported by the best medical and genetics

Michäel Herman, Business Development Manager of OncoDNA, said: “It’s really a great
opportunity for OncoDNA to rely on such a highly renowned and expert partner. Whether it be
through the high scientific level of interactions with the oncologists’ community or through its
dynamic and supportive sales force, BioSequence is a partner of choice to improve
OncoDEEP’s use and awareness in Spain, keeping the patient’s treatment improvement as key

Adriana Terrádez, Business Development Manager of BioSequence commented: “This
agreement with OncoDNA will enable Spanish physicians to access molecular diagnostic
information based on next gen sequencing for their treatment decisions and demonstrate the
use of such information to improve patient outcomes. We were very impressed by the
OncoSHARE web platform and also by the e-learning solution developed by OncoDNA in
collaboration with the University of Brussels. That’s the reason why BioSequence will be the first
partner that offers to its oncologists and patients a customized interface of OncoSHARE, to help
them manage, query and share all their genomic studies”.

About OncoDNA SA
Based in Belgium, OncoDNA is a leading company specialised in the personalized analysis of
tumor DNA. OncoDNA currently has two services, OncoDEEP and OncoTRACE, used for the
targeted sequencing or complete sequencing of tumor genomes. These medical innovations
assist medical doctors with treatment choice and/or provide better monitoring of tumor evolution
in patients. For more information, please visit

BioSequence is the first company to introduce the latest advances in precision oncology in the
Spanish clinical practice. BioSequence collaborates with top international laboratories to provide
cutting edge tumor molecular profiling technologies that enable oncologists to deliver tailored
therapeutic options to their patients. For more information, please visit


For more information, contact:

Michäel Herman

Business Development Manager
1 Rue Louis Breguet
6041 Gosselies, Belgium
Tel. +32 71 347899

Adriana Terradez

Business Development Manager
BioSequence S.L.
Parque Tecnológico de Valencia
Nave 13, Ronda Auguste y Louis Lumière, 23
46980 Paterna (Valencia) – España
Tel. +34961027432